As of October 27, 2026, Bolt Biotherapeutics, Inc. is a publicly traded company (Nasdaq: BOLT); its largest reported holder is Renaissance Technologies, with 5.13% on Schedule 13G of August 13, 2026. The largest insider holding is William P. Quinn, the chief executive and president, with 25,384 shares (1.3% of shares outstanding), per Form 4 of September 21, 2026 (Schedule 13G, August 13, 2026).
About to sign with, pay or invest in Bolt Biotherapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Bolt Biotherapeutics, Inc. a real, registered company?
- Bolt Biotherapeutics, Inc. files with the SEC under CIK 1641281 (its SEC filings).
- Its shares are listed under the ticker BOLT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Redwood City, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Bolt Biotherapeutics, Inc. in our court records and SEC 8-K records (as of 2026-10-27).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2025-10-02, about 20 jobs).
- Leadership changes: the latest reported is Sheila Gujrathi, Director (Form 8-K filed 2026-10-23). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Renaissance Technologies (filed 2026-08-13).
Who are Bolt Biotherapeutics, Inc.'s owners and officers?
Bolt Biotherapeutics, Inc.: incorporated in Delaware; business address in Redwood City, California; industry Pharmaceutical Preparations (Form D, 2026-10-23).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-13 | Renaissance Technologies LLC | 5.13% |
| Schedule 13D/A, 2026-02-26 | Pivotal Bioventure Partners Fund I, L.P. | 4.6% |
| Schedule 13D/A, 2026-02-17 | Pivotal Bioventure Partners Fund I, L.P. | 6.7% |
| Schedule 13G/A, 2026-02-13 | Vivo Panda Fund, L.P. | 3.8% |
| Schedule 13G/A, 2025-11-14 | Tang Capital Management, LLC | 3.5% |
| Schedule 13G/A, 2025-11-14 | Tang Capital Management, LLC | 3.5% |
| Schedule 13G/A, 2025-08-14 | Tang Capital Management, LLC | 8.7% |
Want the whole picture on Bolt Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bolt Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bolt Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-10-23 | Sheila Gujrathi | Director | appointed | |
| Form 8-K, 2026-10-23 | Sheila Gujrathi | Chief Strategy Officer | appointed |
Which insiders own Bolt Biotherapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 25,384 shares (1.3% of shares outstanding) (Form 4, 2026-09-21).
- , the chief operating officer: 17,269 shares (0.90% of shares outstanding) (Form 4, 2026-09-21).
- , the senior vice president and finance: 17,082 shares (0.89% of shares outstanding) (Form 4, 2026-09-21).
Shares outstanding: 1,926,345 as of 2026-08-04, from the company's latest SEC cover page.
How much has Bolt Biotherapeutics, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-10-23).
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2025-10-02).
Keep reading
More on Bolt Biotherapeutics, Inc. and the records around it.
Bolt Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Layoff notices Oct 2025
Companies that share a holder
- Nan Fung Group Holdings Limited also filed stake reports on 2 other companies: Evommune, Inc. (Feb 2026), Oculis Holding AG (Nov 2025)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 32 other companies: Skye Bioscience, Inc. (Oct 2026), Atea Pharmaceuticals, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- Renaissance Technologies LLC also filed stake reports on 46 other companies: AMERICAN PUBLIC EDUCATION INC (Aug 2026), Commercial Vehicle Group, Inc. (Aug 2026), CORCEPT THERAPEUTICS INC (Aug 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/bolt-biotherapeutics